An observational study in Inflammatory Bowel Diseases, Crohn's Disease and Ulcerative Colitis, sponsored by Target PharmaSolutions, Inc.. Active, not recruiting at 37 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Target PharmaSolutions, Inc. · Observational
Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 4th largest by planned enrollment of the 132 observational ones that give a count, is one of 28 that started in 2017, is one of 133 observational ones, reaches primary completion later than 41 of the 121 other live ones, and was the 218th registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 426 are open to participants now.
Browse Inflammatory Bowel Diseases studies →103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Palisade Bio · Sites in United States, Canada, Czechia and 9 more countries
Eli Lilly and Company · Sites in United States, Canada, Denmark and 4 more countries
University of Michigan · Sites in United States
Hope Biosciences Research Foundation · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 278 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 118 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 83 · Phase 3 46 · Phase 4 31
First in 1995; this study’s year is marked. 28 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.
Median enrollment 50 across the 327 interventional studies, 134 across the 132 observational. Of the 301 that completed or were terminated, 120 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 463 have an industry lead sponsor. The 10 most frequent:
Target PharmaSolutions, Inc. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.
Target PharmaSolutions, Inc. has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
42 of the studies in Inflammatory Bowel Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT07769437University Hospitals Cleveland Medical CenterNon-nutritive Sweeteners in Inflammatory Bowel Disease | 2026-12 |
| NCT06065228Children's National Research InstituteTherapeutic Endpoint in Pediatric IBD Conditions | 2026-12 |
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Adults and children (age 2 or older) with a diagnosis of Crohn's disease, Ulcerative colitis, or Indeterminate colitis having been prescribed any IBD treatment outside of a clinical trial
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Natural history of Inflammatory Bowel Disease: Characteristics of IBD
Time frame: Up to 5 years
Natural history of Inflammatory Bowel Disease: Participant demographics
Time frame: Up to 5 years
Natural history of Inflammatory Bowel Disease: Treatment use
Time frame: Up to 5 years
Natural history of Inflammatory Bowel Disease: Treatment response
Time frame: Up to 5 years
Natural history of Inflammatory Bowel Disease: Disease progression
Time frame: Up to 5 years
Endoscopic measures of mucosal healing
Time frame: Up to 5 years
Adverse event frequency and severity
Time frame: Every 3 months for 5 years
Timepoint of clinical response
Time frame: Every 3 months for 5 years
Timepoint of endoscopic response
Time frame: Up to 5 years
Reasons for treatment discontinuation
Time frame: Up to 5 years
Self-reported patient health measures: EQ-5D
Time frame: Every 3 months for 5 years
Self-reported patient health measures: PRO-2 for Crohn's Disease
Time frame: Every 3 months for 5 years
Self-reported patient health measures: PRO-2 for Ulcerative colitis
Time frame: Every 3 months for 5 years
Self-reported patient health measures: 2-question Adherence Measure
Time frame: Every 3 months for 5 years
Self-reported patient health measures: Manitoba IBD Index (MIBDI)
Time frame: Every 3 months for 5 years
Self-reported patient health measures: Pediatric Ulcerative colitis Activity Index (PUCAI)
Time frame: Every 3 months for 5 years
Timepoint of endoscopic remission
Time frame: Up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2017 (actual). Primary completion is estimated for Mar 2027, 116 months after the start.
Of 37 industry-sponsored observational studies under Inflammatory Bowel Diseases, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 44. This study's planned 116 months is above that.
Counting every sponsor, half of 280 studies reached it within 36 months; a quarter within 20 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Target PharmaSolutions, Inc.